Randox response to comments within Sunday Times article 18th October 2020

Home - Sunday Times

Randox response to comments within Sunday Times article 18th October 2020

Randox Logo

   

Randox response to comments within Sunday Times article 18th October:

Randox rejects comments made in the Sunday Times on 18th October, related to Randox’s contribution to the UK’s Covid-19 national testing programme, as misleading and inaccuate.

Randox have committed, through private investment, to the rapid growth of Covid-19 testing capacity within the UK. Indeed Randox are successfully operating at considerable scale and are currently providing well in excess of the testing capacity we have committed to the UK’s testing programme.

The vast majority of samples are reported within 24 hours of entering our laboratories.

Those samples that are found to be unsuitable for processing on receipt at our facilities, and are therefore voided, are not the responsibility of Randox. Such samples are voided when issues have arisen during sample collection and logistic processes, controlled by other parties.

It should also be noted that the proportion of samples found to be unsuitable on receipt at our facilities are both very low and comparable with all other laboratories across the programme.

Randox remain committed to supporting the UK’s Covid-19 testing programme and fully understand the importance of our work to the social and economic well being of the nation.

Press enquiries should be emailed to randox@newcenturymedia.co.uk 

 

Randox in the media

Latest News

FAQs


Randox response to Sunday Times Article 20 September 2020

Randox Logo

   

STATEMENT FROM RANDOX: 20 September 2020

Key Points:

  • Randox has committed 99% of its Covid-19 testing capacity to the national testing programme.
  • Randox are fully committed to the national testing programme and robustly refute accusations within today’s Sunday Times.
  • On 19th September Randox successfully reported to the national programme almost 10,000 samples beyond its committed daily rate.
  • The majority of samples which are voided at Randox are down to logistical reasons outside Randox’s control. Samples voided at Randox’s laboratories are comparable to other laboratories across the programme.  Every voided sample is properly accounted for.
  • Randox does not prioritise private samples over comparable samples within the testing programme.
  • Randox staff have performed extraordinarily well and are our strongest asset.
  • All Randox investment in rapidly increasing capacity to the national testing programme has been through its own private resources.

Randox are fully committed to supporting the national Covid-19 testing programme and fully recognise the importance of this work to the economic and social well-being of the nation.   We have made significant private investment to increase capacity and drive process improvements.  We work very closely with all partners within the programme to ensure the most effective possible testing.

Randox robustly refutes accusations in today’s Sunday Times (Sunday 20th September 2020) that private samples are prioritised over comparable samples within the national testing programme.

This is a gross mis-representation of the facts on the ground with regard to its processes.

We reiterate that Randox does not prioritise private samples over comparable samples from the national testing programme.

Once processed into Randox’s laboratories the vast majority of all samples are reported on within 24 hours. It is inaccurate and unreliable to claim that Randox has completed fewer than one in 10 tests on time.  In fact Randox is successfully meeting and exceeding the capacity requirements agreed with Government and fulfilling its contractual obligations.  Moreover Randox is successfully reporting above our commitment to Government for the national testing programme.

On average the Randox void rate is comparable across the programme. It is important to note that whilst all laboratories conduct the voiding  of samples, the reason for the voiding most frequently lies outside the laboratory – normally user or logistic type issues.  It is extremely inaccurate and misleading to claim that Randox, or indeed any laboratory,  voids samples without explanation.

Every sample is receipted in accordance with stipulated, formal procedures and processed accordingly. This includes cross-referencing every sample barcode electronically with the national registration database. Every sample is appropriately accounted for and samples will only be voided if, due to the quality of the sample, the results could not be guaranteed as reliable. Every sample is fully assessed and if voided is allocated a formal reason for void, and all void statistics are reported daily to Government for further analysis.

It is important to note that Randox is not responsible for the sample logistics of the national programme and, as requested by the national programme, often receives samples in excess of daily capacity to report on within the following days.  This is manageable given the time that samples remain valid.

Randox is a private sector diagnostics company, has been in operation since 1982 and operates in 145 countries across the globe. As such Randox have experience of a wide range of public and private sector responsibilities. Randox takes great care in meeting all of its contractual obligations and fully recognises the critical importance of meeting those obligations with regard to the national testing programme.

Randox does not prioritise commercial work ahead of other work streams.

As stated to the Sunday Times, staffing levels are not an issue and holidays have not impacted on throughput – Randox is currently successfully above our commitment to government.

We reiterate that Owen Paterson MP has played no role in securing any Randox contract with DHSC.

Randox staff have been extraordinary in their commitment and dedication in meeting unparalleled need at a time of national crisis, often in the face of ill-informed and misplaced criticism.  We salute our staff.

Press enquiries should be emailed to randox@newcenturymedia.co.uk 

 

Randox in the media

Latest News

FAQs


Randox response to Sunday Times Article 13 September 2020

Randox Logo

   

STATEMENT FROM RANDOX: 13 September 2020

Randox analyse samples and provide Covid-19  test results through the national portal as efficiently as possible, and those tested will receive their results by text and email.    The vast majority of those tested will receive negative or positive results.

Otherwise, a small minority of samples may be voided for reasons such as leaking or damaged tubes, or have time expired.  Those being tested are made aware that samples only remain valid for a limited period once collected, and those periods of validity are fully understood across the planning and logistic process. Randox have no responsibility for the logistics of sample delivery to laboratories.

Should samples enter the laboratory outside that period the results could not be relied upon; the sample could give a false result and would be voided.  In all void circumstances individuals are advised by the national program to seek a retest.  Randox, and the Government planners, take every precaution possible to minimise voids, understanding that each sample is of critical importance.

A test can only be voided once it is processed and reviewed within our laboratory system, including cross referencing each barcode electronically with the national registration database.

Randox Laboratories are committed to supporting the Government’s response to the Covid-19 pandemic and play an important role in national network of Pillar 2 (outside the NHS) laboratories testing those who may be currently infected with Covid-19.  Such testing is critical to the timely identification and containment of Covid-19 outbreaks and to reduce further spread.   It is acknowledged that the success of the testing program is essential to the social and economic well-being of the nation.

To support our operations Randox liaise very closely with Government planners responsible for the national collection and distribution of samples, and have built an additional 30,000 square feet of laboratory space and employed many more staff in order to increase capacity.  At the time of writing further increases in capacity are being implemented and planned.  Decisions on sample distribution across the Pillar 2 laboratory network are made at a national level.

Randox remain committed to effective and timely Covid-19 testing at scale –  this is work of national importance.

Press enquiries should be emailed to randox@newcenturymedia.co.uk 

Randox in the media

Latest News

FAQs


Request a meeting
×
Make an Enquiry - RX series
×
Make an Enquiry - Reagents
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
×
Make an Enquiry - Quality Control
×
Make an Enquiry - RIQAS
×
Make an Enquiry - RIQAS
×
Make an Enquiry - Quality Control
×
Make an Enquiry
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Biochip
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Molecular
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Future Diagnostics
×
Make an Enquiry - RX series (Product)
×
Make an Enquiry - Quality Control
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - RIQAS
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Por favor, introduzca sus datos para ver nuestro último seminario
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje Polityki Prywatności.
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
×
Wyślij zapytanie
    Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności .
×
귀하의 문의 사항 제출
    Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
귀하의 문의 사항 제출
×
귀하의 문의 사항 제출
×
귀하의 문의 사항 제출
×
Downloads
×
Contact

<p>

    Randox Clinical Chemistry Products Join the Randox Laboratories Mailing List * I would like to receive emails with new product releases and updates from Randox Laboratories, market trends, and more. I do not want to receive email marketing from Randox. Signing up to our mailing list is quick and easy. We do not want to send you any spam or junk emails, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promises never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
</p>

×
Enquire Now - Coronavirus Testing
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details safe and secure. Read more in our Privacy Policy.
×